Intermittent ketoconazole therapy of chronic mucocutaneous candidiasis in childhood.

Abstract

We report the clinical and laboratory findings in two children with chronic mucocutaneous candidiasis (CMC) treated successfully with intermittent long-term ketoconazole therapy. Both had chronic infection of the nails, skin and mucous membranes with positive cultures for candida. Both were resistant to multiple local and systemic antifungal agents. After institution of ketoconazole therapy there was a dramatic improvement with clearing of the oral (one week), skin (two months) and nail lesions (5 months). After 8 months the drug was stopped and clinical remission persisted for 10 and 7 months respectively. Relapse of oral candidiasis was treated with a short course of ketoconazole (4-16 weeks) leading to complete healing of the lesions. Clinical improvement was not related to an amelioration in lymphocyte transformation. There was no change in the progressive deterioration of the lymphocyte responses to candida antigen which was probably due to persisting candida cell wall components (e.g. mannan).

• Authors: S Fanconi, R Seger, P Joller, C Issler, G Schär
• Journal: European journal of pediatrics (Eur J Pediatr) Vol. 139 Issue 3 Pg. 176-80 (Nov 1982) ISSN: 0340-6199 [Print] Germany
• PMID: 6297913 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Imidazoles
• Piperazines
• Ketoconazole

Topics

• Administration, Oral
• Adolescent
• Antifungal Agents (administration & dosage, therapeutic use)
• Candidiasis (drug therapy)
• Candidiasis, Chronic Mucocutaneous (drug therapy, immunology)
• Drug Administration Schedule
• Female
• Humans
• Imidazoles (therapeutic use)
• Ketoconazole
• Lymphocyte Activation
• Male
• Piperazines (therapeutic use)